MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-21-2026
Galmed Pharmaceuticals Ltd. Operating Income 2011-2026 | GLMD
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Galmed Pharmaceuticals Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -30.2 M | -22.4 M | -10.7 M | -12.4 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.7 M | -30.2 M | -18.9 M |
Quarterly Operating Income Galmed Pharmaceuticals Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | -5.82 M | - | - | - | -4.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.7 M | -5.82 M | -5.26 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Immatics N.V.
IMTX
|
-86.3 M | $ 9.4 | -1.16 % | $ 591 M |  Germany |
 |
Incyte Corporation
INCY
|
1.51 B | $ 90.47 | 0.02 % | $ 17.7 B |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | Germany |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 215.49 | -1.18 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 19.43 | 1.04 % | $ 908 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
CytomX Therapeutics
CTMX
|
-22.4 M | $ 4.19 | -5.95 % | $ 578 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-17.3 M | $ 0.72 | 18.96 % | $ 8.25 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Exelixis
EXEL
|
872 M | $ 41.39 | -0.05 % | $ 11.2 B | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.35 | -3.57 % | $ 344 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
ChemoCentryx
CCXI
|
-130 M | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.59 | -1.52 % | $ 16.3 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-38.2 M | $ 4.29 | -3.05 % | $ 822 M | Canada |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
-214 M | $ 69.54 | -1.77 % | $ 11.1 B | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Cara Therapeutics
CARA
|
-121 M | - | -3.03 % | $ 260 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
208 M | $ 27.01 | -2.14 % | $ 1.55 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |